The following table presents various financial information for each reportable segment for the years ended September 30:
|
|
|
|
|
|
|
|
|
|
|
|
|
(In millions) |
|
2026 |
|
|
2025 |
|
|
2024 |
|
Sales |
|
|
|
|
|
|
|
|
|
Life Sciences |
|
$ |
671 |
|
|
$ |
641 |
|
|
$ |
810 |
|
Personal Care |
|
|
592 |
|
|
|
577 |
|
|
|
634 |
|
Specialty Additives |
|
|
504 |
|
|
|
511 |
|
|
|
572 |
|
Intermediates |
|
|
135 |
|
|
|
137 |
|
|
|
144 |
|
Intersegment sales(a) |
|
|
(39 |
) |
|
|
(42 |
) |
|
|
(47 |
) |
|
|
$ |
1,863 |
|
|
$ |
1,824 |
|
|
$ |
2,113 |
|
Cost of sales |
|
|
|
|
|
|
|
|
|
Life Sciences |
|
$ |
411 |
|
|
$ |
418 |
|
|
$ |
515 |
|
Personal Care |
|
|
350 |
|
|
|
345 |
|
|
|
398 |
|
Specialty Additives |
|
|
423 |
|
|
|
433 |
|
|
|
522 |
|
Intermediates |
|
|
117 |
|
|
|
121 |
|
|
|
107 |
|
Intersegment sales |
|
|
(39 |
) |
|
|
(42 |
) |
|
|
(47 |
) |
|
|
$ |
1,262 |
|
|
$ |
1,275 |
|
|
$ |
1,495 |
|
Selling, general and administrative expense |
|
|
|
|
|
|
|
|
|
Life Sciences |
|
$ |
97 |
|
|
$ |
77 |
|
|
$ |
89 |
|
Personal Care |
|
|
87 |
|
|
|
84 |
|
|
|
95 |
|
Specialty Additives |
|
|
70 |
|
|
|
64 |
|
|
|
61 |
|
Intermediates |
|
|
6 |
|
|
|
7 |
|
|
|
7 |
|
Total operating segments |
|
|
260 |
|
|
|
232 |
|
|
|
252 |
|
Unallocated and other |
|
|
117 |
|
|
|
112 |
|
|
|
152 |
|
|
|
$ |
377 |
|
|
$ |
344 |
|
|
$ |
404 |
|
Research and development expense |
|
|
|
|
|
|
|
|
|
Life Sciences |
|
$ |
14 |
|
|
$ |
15 |
|
|
$ |
15 |
|
Personal Care |
|
|
23 |
|
|
|
25 |
|
|
|
26 |
|
Specialty Additives |
|
|
14 |
|
|
|
12 |
|
|
|
11 |
|
Intermediates |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Total operating segments |
|
|
51 |
|
|
|
52 |
|
|
|
52 |
|
Unallocated and other |
|
|
4 |
|
|
|
2 |
|
|
|
3 |
|
|
|
$ |
55 |
|
|
$ |
54 |
|
|
$ |
55 |
|
Intangibles amortization expense |
|
|
|
|
|
|
|
|
|
Life Sciences |
|
$ |
18 |
|
|
$ |
18 |
|
|
$ |
23 |
|
Personal Care |
|
|
32 |
|
|
|
35 |
|
|
|
43 |
|
Specialty Additives |
|
|
9 |
|
|
|
9 |
|
|
|
10 |
|
Intermediates |
|
|
1 |
|
|
|
1 |
|
|
|
— |
|
|
|
$ |
60 |
|
|
$ |
63 |
|
|
$ |
76 |
|
Equity and other income |
|
|
|
|
|
|
|
|
|
Life Sciences |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Personal Care |
|
|
1 |
|
|
|
1 |
|
|
|
— |
|
Specialty Additives |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Intermediates |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Total operating segments |
|
|
1 |
|
|
|
1 |
|
|
|
— |
|
Unallocated and other |
|
|
3 |
|
|
|
3 |
|
|
|
6 |
|
|
|
$ |
4 |
|
|
$ |
4 |
|
|
$ |
6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In millions) |
|
2026 |
|
|
2025 |
|
|
2024 |
|
Goodwill impairment and loss on divestitures, net |
|
|
|
|
|
|
|
|
|
Life Sciences |
|
$ |
— |
|
|
$ |
375 |
|
|
$ |
— |
|
Personal Care |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Specialty Additives |
|
|
— |
|
|
|
331 |
|
|
|
— |
|
Intermediates |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Total operating segments |
|
|
— |
|
|
|
706 |
|
|
|
— |
|
Unallocated and other |
|
|
8 |
|
|
|
161 |
|
|
|
115 |
|
|
|
$ |
8 |
|
|
$ |
867 |
|
|
$ |
115 |
|
Operating income (loss) |
|
|
|
|
|
|
|
|
|
Life Sciences(b) |
|
$ |
131 |
|
|
$ |
(262 |
) |
|
$ |
168 |
|
Personal Care(c) |
|
|
101 |
|
|
|
90 |
|
|
|
73 |
|
Specialty Additives(d) |
|
|
(12 |
) |
|
|
(338 |
) |
|
|
(32 |
) |
Intermediates |
|
|
11 |
|
|
|
8 |
|
|
|
29 |
|
Total operating segments |
|
|
231 |
|
|
|
(502 |
) |
|
|
238 |
|
Unallocated and other(e) |
|
|
(126 |
) |
|
|
(273 |
) |
|
|
(264 |
) |
Total operating income (loss) |
|
$ |
105 |
|
|
$ |
(775 |
) |
|
$ |
(26 |
) |
Net interest and other expense (income) |
|
|
40 |
|
|
|
33 |
|
|
|
(24 |
) |
Other net periodic benefit (income) loss |
|
|
(4 |
) |
|
|
1 |
|
|
|
22 |
|
Income (loss) from continuing operations before income taxes |
|
$ |
69 |
|
|
$ |
(809 |
) |
|
$ |
(24 |
) |
|
|
|
|
|
|
|
|
|
|
EBITDA(f) |
|
|
|
|
|
|
|
|
|
Life Sciences |
|
$ |
187 |
|
|
$ |
(187 |
) |
|
$ |
229 |
|
Personal Care |
|
|
161 |
|
|
|
155 |
|
|
|
152 |
|
Specialty Additives |
|
|
51 |
|
|
|
(254 |
) |
|
|
89 |
|
Intermediates |
|
|
16 |
|
|
|
21 |
|
|
|
42 |
|
Total operating segments |
|
|
415 |
|
|
|
(265 |
) |
|
|
512 |
|
Unallocated and other |
|
|
(125 |
) |
|
|
(273 |
) |
|
|
(264 |
) |
Total EBITDA |
|
$ |
290 |
|
|
$ |
(538 |
) |
|
$ |
248 |
|
Depreciation expense |
|
|
125 |
|
|
|
174 |
|
|
|
198 |
|
Amortization expense |
|
|
60 |
|
|
|
63 |
|
|
|
76 |
|
Net interest and other expense (income) |
|
|
40 |
|
|
|
33 |
|
|
|
(24 |
) |
Other net periodic benefit (income) loss |
|
|
(4 |
) |
|
|
1 |
|
|
|
22 |
|
Income (loss) from continuing operations before income taxes |
|
$ |
69 |
|
|
$ |
(809 |
) |
|
$ |
(24 |
) |
|
|
|
|
|
|
|
|
|
|
Depreciation expense |
|
|
|
|
|
|
|
|
|
Life Sciences(g) |
|
$ |
38 |
|
|
$ |
57 |
|
|
$ |
38 |
|
Personal Care(h) |
|
|
28 |
|
|
|
30 |
|
|
|
36 |
|
Specialty Additives(i) |
|
|
54 |
|
|
|
75 |
|
|
|
111 |
|
Intermediates |
|
|
4 |
|
|
|
12 |
|
|
|
13 |
|
Total operating segments |
|
|
124 |
|
|
|
174 |
|
|
|
198 |
|
Unallocated and other(j) |
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
$ |
125 |
|
|
$ |
174 |
|
|
$ |
198 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In millions) |
|
2026 |
|
|
2025 |
|
|
2024 |
|
Additions to property, plant and equipment |
|
|
|
|
|
|
|
|
|
Life Sciences |
|
$ |
31 |
|
|
$ |
49 |
|
|
$ |
61 |
|
Personal Care |
|
|
9 |
|
|
|
7 |
|
|
|
11 |
|
Specialty Additives |
|
|
42 |
|
|
|
34 |
|
|
|
61 |
|
Intermediates |
|
|
4 |
|
|
|
3 |
|
|
|
2 |
|
Unallocated and other |
|
|
2 |
|
|
|
5 |
|
|
|
2 |
|
|
|
$ |
88 |
|
|
$ |
98 |
|
|
$ |
137 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In millions) |
|
2026 |
|
|
2025 |
|
Assets |
|
|
|
|
|
|
Life Sciences |
|
$ |
1,422 |
|
|
$ |
1,498 |
|
Personal Care |
|
|
701 |
|
|
|
751 |
|
Specialty Additives |
|
|
964 |
|
|
|
1,020 |
|
Intermediates |
|
|
116 |
|
|
|
116 |
|
Unallocated and other |
|
|
1,324 |
|
|
|
1,226 |
|
|
|
$ |
4,527 |
|
|
$ |
4,611 |
|
Property, plant and equipment - net |
|
|
|
|
|
|
Life Sciences |
|
$ |
440 |
|
|
$ |
481 |
|
Personal Care |
|
|
106 |
|
|
|
101 |
|
Specialty Additives |
|
|
463 |
|
|
|
484 |
|
Intermediates |
|
|
31 |
|
|
|
30 |
|
Unallocated and other |
|
|
94 |
|
|
|
105 |
|
|
|
$ |
1,134 |
|
|
$ |
1,201 |
|
|
|
|
|
|
|
|
(a)Intersegment sales from Intermediates are accounted for at prices that approximate market value. All other intersegment sales are accounted for at cost. (b)Includes $16 million of capital projects impairment charges in 2026 and goodwill impairment of $375 million for Life Sciences in 2025. (c)Includes capital projects impairment charge of $11 million for Personal Care in 2024. (d)Includes $2 million of capital projects impairment charges in 2026 and goodwill impairment of $331 million for Specialty Additives in 2025. (e)Includes a $3 million gain on sale of excess corporate properties, a $2 million excess land contract termination fee income and a $13 million Argentina foreign currency cumulative translation adjustment in 2026, $8 million gain on sale and a $183 million impairment charge related to the divestiture of the Avoca business in 2025, and a $8 million loss on sale and a $99 million impairment charge related to the divestiture of the Nutraceuticals business in 2024 within the loss on divestitures, net. (f)Excludes loss from discontinued operations, net of income taxes and other net periodic benefit (income) loss. See the Statements of Consolidated Comprehensive Income (Loss) for applicable amounts excluded. (g)Depreciation includes accelerated depreciation of $21 million for Life Sciences in 2025. (h)Depreciation includes accelerated depreciation of $1 million, $1 million and $2 million for Personal Care in 2026, 2025 and 2024, respectively. (i)Depreciation includes accelerated depreciation of $3 million, $19 million and $55 million for Specialty Additives in 2026, 2025 and 2024, respectively. (j)Depreciation includes accelerated depreciation of $1 million for Unallocated and other in 2026.
|